MARKET

CYCC

CYCC

Cyclacel Pharma
NASDAQ
0.2910
-0.0180
-5.83%
Closed 19:31 12/06 EST
OPEN
0.3003
PREV CLOSE
0.3090
HIGH
0.3003
LOW
0.2805
VOLUME
205.28K
TURNOVER
0
52 WEEK HIGH
1.170
52 WEEK LOW
0.2520
MARKET CAP
3.68M
P/E (TTM)
-0.1470
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CYCC last week (1127-1201)?
Weekly Report · 3d ago
Cyclacel Pharmaceuticals regains compliance with Nasdaq listing rules
Healthcare cyclacel pharmaceuticals regains compliance with nasdaq listing rules. Shares of cycc jumped 7.8% in early trading. Cycc said it had received a nasdaq notice stating it had regained compliance with listing rules in early thursday morning.
Seeking Alpha · 6d ago
Why Salesforce Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
Salesforce, inc. Shares surged in pre-market trading after the company reported third-quarter financial results and issued fy24 guidance above estimates. Aditxt shares rose 126.1% to $7.80 on wednesday. Ampio pharmaceuticals, ampio shares surged 37.7% on wednesday after reporting better-than-expected results.
Benzinga · 11/30 13:01
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Riskon international (nasdaq:roi) stock is rocketing 78% higher alongside insider buying. Esgl holdings shares are soaring more than 63% after announcing a new multi-year contract. Risk on international is among the biggest pre-market stock movers on tuesday morning.
Investorplace · 11/28 12:29
Weekly Report: what happened at CYCC last week (1120-1124)?
Weekly Report · 11/27 10:58
Why Guess? Shares Are Trading Lower By Around 15%; Here Are 20 Stocks Moving Premarket
Guess?, inc. Shares dipped in pre-market trading after the company reported worse-than-expected third-quarter financial results. Guess? also issued fourth-quarter adjusted eps guidance below estimates. Agilethought, inc. And anghami limited jumped 97% and 25% respectively in premarket trading.
Benzinga · 11/22 12:58
Weekly Report: what happened at CYCC last week (1113-1117)?
Weekly Report · 11/20 10:56
Cyclacel Pharmaceuticals Convertible Exchangeable Preferred Stock Shares Cross 6.5% Yield Mark
NASDAQ · 11/15 22:42
More
About CYCC
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The anti-mitotic program is evaluating plogosertib, a PLK1 inhibitor, in solid tumors and hematological malignancies. The Company's Mitosis Regulation program includes Plogosertib, which is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor. Plogosertib has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and impressive efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in acute leukemias and solid tumors.

Webull offers Cyclacel Pharmaceuticals Inc stock information, including NASDAQ: CYCC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYCC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CYCC stock methods without spending real money on the virtual paper trading platform.